Targeting G9a to develop Covid-19 and Long Covid treatments

Inhibiting the G9a protein could help stop the COVID-19 virus from hijacking our cells to replicate, offering a new way to treat COVID-19.

For Long COVID, targeting G9a might also help alleviate lingering symptoms by potentially reversing the virus's long-term impacts on our bodies.

Based on a recent dissertation:

https://www.cell.com/cell-chemical-biology/abstract/S2451-94...

A novel G9a inhibitor has been identified that has been seen helpful for Alzheimer's as well:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690335/

> Thus, in contrast to existing AD therapies that only slow one symptom (e.g., cognitive decline) targeting AD-activated G9a by the brain-penetrant drug MS1262 showed multifaceted effects that relieve all AD symptoms with minimum side effect.